Citation Impact
Citing Papers
Blockade of Myeloid-Derived Suppressor Cell Expansion with All- Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy
2018
Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign
2010
PD-1 Blunts the Function of Ovarian Tumor–Infiltrating Dendritic Cells by Inactivating NF-κB
2015
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination
2005
Toll-like Receptor 9 Activation of Signal Transducer and Activator of Transcription 3 Constrains Its Agonist-Based Immunotherapy
2009
Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies
2015
Activation of the Signal Transducers and Activators of the Transcription 3 Pathway in Alveolar Epithelial Cells Induces Inflammation and Adenocarcinomas in Mouse Lung
2007
Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody
2016
Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion
2007
Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
2010
Mechanism of All- Trans Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells
2007
Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer
2010
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Immunological aspects of cancer chemotherapy
2007
Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells
2009
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
2009 Standout
Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
2009
Mycobacterium bovis Bacillus Calmette-Guérin Vaccination Mobilizes Innate Myeloid-Derived Suppressor Cells Restraining In Vivo T Cell Priming via IL-1R–Dependent Nitric Oxide Production
2010
Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
2009
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
2011
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
New insights into myeloid-derived suppressor cells and their roles in feto-maternal immune cross-talk
2015
Hallmarks of Cancer: The Next Generation
2011 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Combinatorial Cancer Immunotherapy
2006
Myeloid-derived suppressor cells coming of age
2018 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Interleukin-22 but Not Interleukin-17 Provides Protection to Hepatocytes during Acute Liver Inflammation
2007
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
2008 StandoutNature
Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
2012
MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation
2019
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
2010
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Alarmins: awaiting a clinical response
2012
Pathogenesis and therapy of psoriasis
2007 StandoutNature
Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients
2013
Imaging in the era of molecular oncology
2008 StandoutNature
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
2016
Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression
2009
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity
2008 StandoutNature
Coordinated regulation of myeloid cells by tumours
2012 Standout
Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
2013
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
2012
Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus
2020
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
2008
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
2007
Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation
2018
Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis
2017
Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer
2005
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Human nutrition, the gut microbiome and the immune system
2011 StandoutNature
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Role of the Microbiota in Immunity and Inflammation
2014 Standout
The complexity of NF-κB signaling in inflammation and cancer
2013 Standout
Immune surveillance of tumors
2007
Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
2013
Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function
2010
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Inflammatory cell infiltration of tumors: Jekyll or Hyde
2007
Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab
2013
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Contribution of MyD88 to the Tumor Exosome-Mediated Induction of Myeloid Derived Suppressor Cells
2010
Getting under the skin: the immunogenetics of psoriasis
2005
The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts
2011
Immunity, Inflammation, and Cancer
2010 Standout
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
2013
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice
2011
Immunosurveillance of pancreatic adenocarcinoma: Insights from genetically engineered mouse models of cancer
2008
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
2016
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
STATs in cancer inflammation and immunity: a leading role for STAT3
2009 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
2009
Microenvironmental regulation of metastasis
2008 Standout
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
2016
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
2004
STAT3 activation
2013
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
2006
Myeloid‐derived suppressor cell activation by combined LPS and IFN‐γ treatment impairs DC development
2009
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
2012
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
Damage-associated molecular patterns in cancer: a double-edged sword
2016
History of myeloid-derived suppressor cells
2013
Regulation of immune responses by L-arginine metabolism
2005
Cancer-related inflammation
2008 StandoutNature
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
2017
Managing Adverse Events With Immune Checkpoint Agents
2016
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Opportunistic infections in patients treated with immunotherapy for cancer
2014
Myeloid-Derived Suppressor Cells in Bacterial Infections
2016
Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor
2010
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
2016 Standout
Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients
2013
Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth
2009
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Myeloid-Derived Suppressor Cells
2017
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
2016 Standout
Anti‐IL ‐6 receptor mA b eliminates myeloid‐derived suppressor cells and inhibits tumor growth by enhancing T ‐cell responses
2012
Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses
2007
Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease
2005
Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression
2014
Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer
2004
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
2015
Managing Immune Checkpoint-Blocking Antibody Side Effects
2015
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
2014
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients
2006
Reversal of Myeloid Cell–Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma
2008
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
2010
Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies
2015
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Therapeutic Targeting of the Tumor Microenvironment
2021
Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
2013
Myeloid‐derived suppressor cell heterogeneity in human cancers
2014
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
2016
Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages.
2013
Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
2016
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
2012 StandoutNobel
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
2019 Standout
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
2010
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Transcriptional regulation of myeloid-derived suppressor cells
2015
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
2015
Neutrophilic myeloid-derived suppressor cells in cord blood modulate innate and adaptive immune responses
2013
Myeloid-Derived Suppressor Cells in the Development of Lung Cancer
2013
Regulation of Dendritic Cell Differentiation and Antitumor Immune Response in Cancer by Pharmacologic-Selective Inhibition of the Janus-Activated Kinase 2/Signal Transducers and Activators of Transcription 3 Pathway
2005
mTOR inhibitor INK128 attenuates dextran sodium sulfate‐induced colitis by promotion of MDSCs on Treg cell expansion
2018
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
2016
The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
2009
In neonates S100A8/S100A9 alarmins prevent the expansion of a specific inflammatory monocyte population promoting septic shock
2016
Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells
2017
Immune‐Related Adverse Events From Immune Checkpoint Inhibitors
2016
Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function
2010
Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell–expressed FasL
2011
Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer
2017
The Emerging Immunological Role of Post-Translational Modifications by Reactive Nitrogen Species in Cancer Microenvironment
2014
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils
2015
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity
2005
Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer
2020
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis
2013
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice
2011
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
2014
Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4
2009
Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β1
2009
Polyunsaturated fatty acids promote the expansion of myeloid‐derived suppressor cells by activating the JAK /STAT 3 pathway
2013
Works of Bin Yu being referenced
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
2016
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
2012
Stat3 regulates genes common to both wound healing and cancer
2005
All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.
2003
Safety and efficacy of adjuvant anti-PD1 therapy (nivolumab) in combination with vaccine in resected high-risk metastatic melanoma.
2013
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
2013
Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI).
2015
Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
2014
H1° histone and differentiation of dendritic cells. A molecular target for tumor-derived factors
2002
Full-length dominant-negative survivin for cancer immunotherapy.
2003
Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
2010
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
2008
Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer.
2003